Details for New Drug Application (NDA): 211950
✉ Email this page to a colleague
The generic ingredient in XIPERE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 211950
Tradename: | XIPERE |
Applicant: | Bausch And Lomb Inc |
Ingredient: | triamcinolone acetonide |
Patents: | 3 |
Pharmacology for NDA: 211950
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 211950
Suppliers and Packaging for NDA: 211950
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950 | NDA | Bausch & Lomb Incorporated | 24208-040 | 24208-040-01 | 1 TRAY in 1 CARTON (24208-040-01) / 1 VIAL in 1 TRAY / .9 mL in 1 VIAL (24208-040-02) |
XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950 | NDA | Bausch & Lomb Incorporated | 24208-040 | 24208-040-40 | 1 TRAY in 1 CARTON (24208-040-40) / 1 VIAL in 1 TRAY / .9 mL in 1 VIAL (24208-040-41) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;INJECTION | Strength | 40MG/ML | ||||
Approval Date: | Oct 22, 2021 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Oct 22, 2024 | ||||||||
Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Patent: | 8,636,713 | Patent Expiration: | May 2, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS | ||||||||
Patent: | 9,636,332 | Patent Expiration: | Nov 8, 2033 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS |
Complete Access Available with Subscription